Clinical evaluation of the bispecific antibody MDX-H210 (anti-FcγRI x anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (filgrastim) for treatment of advanced breast cancer

Cancer Immunology Immunotherapy

Volumn 45, Issue 3-4, 1997, Pages 207-209

  Van Ojik, Heidi H ^a   Repp, Roland ^b   Groenewegen, Gerard ^a   Valerius, Thomas ^b   Van De Winkel, Jan G J ^a,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Medarex Europa   (Netherlands)

Author keywords

Bispecific antibody; Fc RI; Immunotherapy; Neutrophil; Phase I trial

Indexed keywords

BISPECIFIC ANTIBODY; MDX H210; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG RESEARCH; DRUG SCREENING; FEVER; GRANULOCYTOSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

ADULT; AGED; ANTIBODIES, BISPECIFIC; BREAST NEOPLASMS; FEMALE; FILGRASTIM; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, IGG;

EID: 0030829805     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050434     Document Type: Article

References (19)

1. Deo YM, Graziano RF, Repp R, Winkel JGJ van de (1997) Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies. Immunol Today 18:127
2. Dillman RO (1994) Antibodies as cytotoxic therapy. J Clin Oncol 12:1497
3. Featherstone C (1996) Bispecific Antibodies: the new magic bullets. Lancet 348:536
4. 2 antibody containing thioether-linked Fab′γ fragments. J Immunol 139:2367
5. Graziano RF, Tempest PR, White P, Keler T, Deo Y, Ghebremariam H, Coleman K, Pfefferkorn LC, Fanger MW, Guyre PM (1995) Construction and characterization of a humanized anti-gamma-Ig receptor type I (FcγRI) monoclonal antibody. J Immunol 155:4996
6. Guyre PM, Graziano RF, Vance BA, Morganelli PM, Fanger MW (1989) Monoclonal antibodies that bind to distinct epitopes on FcγRI are able to trigger receptor function. J Immunol 143:1650
7. Harris JR, Lippman ME, Veronesi U, Willett W (1992) Breast cancer (I, II, III). N Engl J Med 327:319, 390, 473
8. Harris J, Morrow M, Norton L (1997) Malignant tumours of the breast: In: DeVita VT, Hellman S Jr, Rosenberg SA (eds) Cancer principles and practice of oncology. Lippincott-Raven, Philadelphia, p 1557
9. Lichtenstein A (1990) Granulocytes as possible effectors of tumour immunity: In: Oettgen (ed) Human cancer immunology. Saunders, Philadelphia, p 731
10. Lieschke GJ, Burgess AW (1992) Drug therapy: granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med 327:28-99
11. Repp R, Valerius T, Wieland G, Becker W, Steininger H, Deo Y, Gramatzki M, Winkel JGJ van de, Lang N, Kalden JR (1995) G-CSF stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to FcγRI and HER-2/neu (MDX210). J Hematother 4:415
12. Riethmüller G, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raab R, Höffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, Buggisch P, Witte J. The German Cancer Aid 17-1A study group (1994) Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 243:1177
13. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ulrich A, Press MF (1989) Studies of the HER-2/neu protooncogene in human breast cancer and ovarian cancer. Science 244:707
14. Stockmeyer B, Valerius T, Repp R, Heijnen IAFM, Buhring HJ, Deo YM, Kalden JR, Gramatzki M, Winkel JGJ van de (1997) Preclinical studies with FcγR bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. Cancer Res 57:696
15. Valerius T, Repp R, de Wit TPM, Berthold S, Platzer E, Kalden JR, Gramatzki M, Winkel JGJ van de (1993) Involvement of the high affinity receptor for IgG (FcγRI; CD64) in enhanced tumour cytotoxicity of neutrophils during G-CSF therapy. Blood 82:931
16. Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Deo Y, Graziano R, Fisher JL, Meyer L, Mrozek-Orlowski M, Wardwell K, Guyre V, Marley TL, Arvizu C, Fanger MW (1995) Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2 /neu. J Clin Oncol 13:2281
17. Wallace PK, Valone FH, Fanger MW (1995) Myeloid cell-targeted cytotoxicity of tumour cells: In: Fanger MW (ed) Bispecific antibodies. Landes, Austin Tex, p 43
18. Weiner LM, Clark JI, Davey M, Li WS, Garcia de Palazzo I, Ring DB, Alpaugh RK (1995) Phase I trial of 2B1, a bispecific monoclonal antibody targeing c-erbB-2 and FcγRIII. Cancer Res 55:4586
19. Winkel JGJ van de, Capel PJA (1993) Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today 14:215